Evidence map›Paper›PMID 26186349›Full record

ArticlePloS one2015

Magnetic Resonance Phase Alterations in Multiple Sclerosis Patients with Short and Long Disease Duration.

Ivan Bozin, Yulin Ge, Joseph Kuchling, Petr Dusek, Sanjeev Chawla, Lutz Harms, Klemens Ruprecht, Thoralf Niendorf, Friedemann Paul, Ilya Kister and 2 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ivan BozinNeuroCure Clinical Research Center, Charité -Universitaetsmedizin Berlin, Berlin, Germany.
Yulin GeDepartment of Radiology, NYU School of Medicine, New York, New York, United States of America.
Joseph KuchlingNeuroCure Clinical Research Center, Charité -Universitaetsmedizin Berlin, Berlin, Germany.
Petr DusekInstitute of Neuroradiology, Universitaetsmedizin Goettingen, Goettingen, Germany; Department of Neurology and Center of Clinical Neuroscience, Charles University in Prague, 1st Faculty of Medicine and General University Hospital in Prague, Prague, Czech Republic.
Sanjeev ChawlaDepartment of Radiology, NYU School of Medicine, New York, New York, United States of America.
Lutz HarmsClinical and Experimental Multiple Sclerosis Research Center, Charité Universitaetsmedizin Berlin, Berlin, Germany; Department of Neurology, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Klemens RuprechtClinical and Experimental Multiple Sclerosis Research Center, Charité Universitaetsmedizin Berlin, Berlin, Germany; Department of Neurology, Charité-Universitaetsmedizin Berlin, Berlin, Germany.
Thoralf NiendorfBerlin Ultrahigh Field Facility, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Experimental and Clinical Research Center, Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany.
Friedemann PaulNeuroCure Clinical Research Center, Charité -Universitaetsmedizin Berlin, Berlin, Germany; Clinical and Experimental Multiple Sclerosis Research Center, Charité Universitaetsmedizin Berlin, Berlin, Germany; Department of Neurology, Charité-Universitaetsmedizin Berlin, Berlin, Germany; Experimental and Clinical Research Center, Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany.
Ilya KisterMultiple Sclerosis Care Center, Department of Neurology, NYU School of Medicine, New York, New York, United States of America.
Tim SinneckerNeuroCure Clinical Research Center, Charité -Universitaetsmedizin Berlin, Berlin, Germany; Department of Neurology, Asklepios Fachklinikum Teupitz, Teupitz, Germany.
Jens WuerfelNeuroCure Clinical Research Center, Charité -Universitaetsmedizin Berlin, Berlin, Germany; Institute of Neuroradiology, Universitaetsmedizin Goettingen, Goettingen, Germany; Berlin Ultrahigh Field Facility, Max Delbrueck Center for Molecular Medicine, Berlin, Germany; Experimental and Clinical Research Center, Charité-Universitaetsmedizin Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe analysis of the MR phase provides additional information on the tissue microstructure. In multiple sclerosis (MS) lesions phase alterations may reflect different stages of inflammatory activity. Here we investigated lesion morphology in MS patients with short and long disease duration on T2* weighted, phase, magnitude and susceptibility weighted imaging (SWI) at 7 Tesla (T).

methods17 MS or clinically isolated syndrome patients with short (<60 months) and 11 with long (>60 months) disease duration underwent 7 T MRI. Lesions were subsequently analyzed side-by-side with regard to morphology and visibility on T2* weighted, SWI, magnitude and SWI-filtered phase images.

results126 of 192 T2* weighted lesions (65.6%) were characterized by a phase alteration pattern, and hence could be differentiated on phase images. In detail, a significantly reduced proportion of lesions showing phase alterations was detectable in patients with longer disease duration (mean±SD 51 ± 37%, range 0-100%) compared to patients with short disease duration (mean ± SD 90 ± 19.5%, range 50-100%, p = 0.003).

conclusionThis cross-sectional study identified different patterns of phase changes in lesions of MS patients with short and long standing disease. Longitudinal studies are warranted to prove that MR phase imaging is useful in determining the activity and the developmental stage of individual MS plaques.

Indexed as

AdultBrainCross-Sectional StudiesDisease ProgressionFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedMultiple SclerosisTime Factors

Identifiers

PMID26186349
PMCPMC4506094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.